Background: Post-translational modifications of tau modify its interaction with binding partners and
Introduction
Genome-wide association studies (GWAS) identified variants of bridging integrator 1 (BIN1) that confer the second largest genetic risk factor for developing sporadic AD, after APOE4 (1-7). BIN1 is a cytoplasmic membrane-binding protein, which plays important roles in endocytosis and subcellular trafficking (8) . BIN1 has a number of splice variants with tissue specific expression (8) . The more common BIN1 variants are upstream of the gene and do not affect protein structure but may affect splicing or expression of BIN1. In AD brain, expression of the longer neuronal forms of BIN1 are decreased, while the shorter glial isoforms are increased (9-11). Chapuis et al. (12) recently reported a 3 base pair insertion in complete linkage disequilibrium with the BIN1 polymorphism rs744373 that is associated with increased mRNA levels of BIN1 (12) , although Adams et al. (13) found no correlation between rs744373 and BIN1 expression. Nevertheless, BIN1 risk polymorphisms at rs744373 are associated with increased BIN1 expression and poorer memory in those with epilepsy (14, 15) .
Alterations to tau protein are closely associated with synaptic dysfunction, neurodegeneration and cognitive decline in AD (16, 17) . Direct interactions between BIN1 and tau have been demonstrated in cell models, mice and Drosophila (12, (18) (19) (20) , BIN1 colocalises with neurofibrillary tangles (11) and is associated with elevated tau phosphorylation in AD brain (21). Importantly, expression of BIN1 in a Drosophila model of AD was recently shown to modulate the toxicity of tau (12) . Others have shown that BIN1 over-expression in mice causes microstructural changes in hippocampal circuits (22) . These are the first circuits to show tau pathology in AD (22), suggesting that BIN1 may affect the development of AD by modulating tau effects at synapses and possibly also synaptic activitydependent tau release (23). Therefore, the purpose of this study was to investigate the functional consequences of interactions between BIN1 and tau for disease-associated tau mis-sorting and release and synapse health.
Materials and methods

Human Brain
Braak staged post-mortem human brain tissue was obtained from the MRC London Neurodegenerative Diseases brain bank at King's College London following ethical approval (REC reference: 08/MRE09/38 + 5). Details of these samples are provided in Tables 1 and 2 .
Modification of BIN1 expression in primary neurons
Primary cortical neurons were dissected from E18 Sprague-Dawley rats and cultured as previously described (24) on poly-D-lysine coated plates or glass cover-slips. Lentivirus shRNA targeting BIN1 from the RNAi consortium (TRCN0000088188) and a scrambled control sequence in the pLKO.1 vector were purchased from Dharmacon Horizon (CO, USA). PAX2 and pMG.2 plasmids were kind gifts from Dr Maria Jimenez-Sanchez (King's College London). HEK293 cells cultured in Dulbecco's Modified Eagle medium plus GlutaMAX (DMEM, Thermo Fisher Scientific, MA, USA) supplemented with 10 % (v/v) fetal bovine serum (FBS, Thermo Fisher Scientific) were transfected with PAX2, pMG.2, and shRNA using Lipofectamine 2000 (Invitrogen, CA, USA). Lentiviral particles collected from culture medium were isolated and concentrated according to the manufacturer's instructions. BIN1 was knocked down using either lentiviral shRNA constructs or Accell siRNA smart pool (E-095528, Dharmacon Horizon).
At 19 days in vitro (DIV), rat primary cortical neurons were transfected with 50 nM BIN1 or nontargeting control siRNA (Dharmacon Horizon Discovery) using Lipofectamine 2000 and incubated for 96 hours at 37 o C before use. For lentiviral knockdown, neurons were cultured for 5 DIV, then treated with either BIN1 targeting shRNA or scrambled control shRNA lentiviral particles for 24 hours, after which time the virus was removed and neurons further cultured until 21-23 DIV.
GST binding assays
BIN1-SH3 cDNA generously provided by Isabelle Landrieu (University of Lille Nord de France) was cloned into pGEX5X1 using sequence and ligation independent cloning (SLIC) (25). The BIN1-SH3 domain was amplified from the original vector using primers 5'-TCG AGC GGC CGC ATC GTG ACA TGG GTC GTC TGG ATC TG-3' and 5'-AAA CGC GCG AGG CAG ATC GTC AGT TAC GGC ACA CGC TCA GTA AAA TTC-3', and pGEX5X1 was linearized using primers 5'-CTG ACG ATC TGC CTC GCG-3' and 5'-GTC ACG ATG CGG CCG CTC-3'. SLIC products were used to transform BL21 E.coli (New England Biolabs, MA, USA) by heat shock. DNA was purified using QIAgen spin miniprep kit (QIAgen, Hilden, Germany) and the cloning was confirmed by sequencing (Source Bioscience, Nottingham, UK, using stock primers to GST plasmid). BL21 E.coli containing either BIN1-SH3-pGEX5X1 or empty vector pGEX5X1 were used to produce glutathione S-transferase (GST) fusion proteins and GST-pulldown assays were performed as described previously (26). WT and PxxP mutant tau plasmids have been described previously (26).
These were expressed in HEK293 cells for 24 hours after which time cells were lysed and the lysates used in GST pull-downs.
Tau ELISA and cell viability assays
Lactate dehydrogenase was measured in culture medium to determine cell health, and sandwich
ELISAs were used to determine tau content in culture medium from neurons incubated for 4 hours in Hank's balanced salt solution (HBSS), without Ca 2+ and Mg 2+ as described previously (27).
Proximity Ligation Assays
23 DIV neurons were fixed in 4 % (w/v) paraformaldehyde in phosphate-buffered saline (PBS) (Alfa Aesar, MA, USA) and non-specific fluorescence quenched by incubation in 50 mM NH4Cl in PBS for 10 minutes, followed by cell permeabilisation in 0.2 % (v/v) Triton X-100 in PBS. Proximity ligation assays (PLAs) were performed using Duo-link reagents (Sigma Aldrich, MO, USA), according to the manufacturer's protocol and with primary antibodies against BIN1 (ab54764, Abcam, Cambridge, UK) and total tau (Agilent, CA, USA). Actin was labelled with phalloidin-488 (Life Technologies, CA, USA), and nuclei stained with 10 μgml -1 Hoescht-33352 (Thermo Fischer Scientific). Image stacks covering the whole volume of each cell were acquired using a Nikon Eclipse Ti-E microscope and analysed using
Fiji. Z-stacks were converted to maximum intensity projections, and the phalloidin signal used to identify cell outlines. The intensity of PLA signals in each cell was quantified using Fiji (28) and is expressed as a proportion of cell area.
PLAs on paraffin-embedded human frontal cortex were performed as described above, with the following additions. Sections were rehydrated and de-waxed using standard methods, and antigen retrieval was performed by 1-hour incubation in 10 mM glycine, 0.25 % (v/v) Triton X-100 in Trisbuffered saline (TBS). Sections were blocked for two hours in 5 % (v/v) horse serum, 0.25 % (v/v) Triton X-100 in TBS. MAP2 (GTX82661, GeneTex, CA, USA) was immunolabelled and detected using Alexa
Fluor-conjugated secondary antibodies (Life Technologies).
Immunofluorescence
Immunofluorescence was performed as described (29), but using 2 % (v/v) fetal bovine serum (FBS, Life Technologies). Cells were incubated with primary antibodies against BIN1 (ab54764, Abcam), PSD-95 (D74D3, Cell Signalling), synaptophysin (sc7568, Santa Cruz, TX, USA) and MAP2 (GTX82661, GeneTex), and the appropriate species of AlexaFluor-conjugated secondary antibody (Life Technologies). Labelled proteins were imaged using an Eclipse Ti2 inverted Nikon 3D N-SIM microscope and images reconstructed using NIS elements software.
Analysis of synapses
Neurons were fractionated to generate a synapse-enriched fraction using a protocol modified from (30). Synaptoneurosomes were isolated from post-mortem temporal cortex as described in (31, 32).
Equal protein concentrations of total, synaptic and cytoplasmic fractions were immunoblotted for tau, BIN1, synaptic and cytoplasmic markers.
Neurons at 22 DIV were transfected with an eGFP-N2 plasmid (Clontech, Kyoto, Japan) using
Lipofectamine 2000 for 24 hours, fixed as described above and imaged using a Nikon Eclipse Ti-2 inverted microscope with Vt-iSIM scan head, 3x3 large image stacks were acquired covering the entire volume of the neuron, with 0.2 μm between each image in the Z plane. Neurolucida TM software (MBF Bioscience, VT, USA) was used to trace neurons and detect, classify and quantify dendritic spines.
SDS-PAGE and western blotting
Samples were electrophoresed on 10 % Tris-glycine-Sodium Dodecyl Sulphate-polyacrylamide gels, Nu-Page 4-12 % or 10 % Bis-Tris gels (Invitrogen), transferred to 0.45 μm nitrocellulose membrane (Millipore, MA, USA) and immunoblotted as described (10) . Primary antibodies were BIN1 (99D, Millipore), GST (GE Healthcare, IL, USA), total tau (total human tau, Agilent), Tau-1 (Millipore), PHF1
(Peter Davies, Donald and Barbara Zucker School of Medicine at Hofstra, Northwell, USA), -actin (ac15, abcam), synaptophysin (sc17750, Santa Cruz), and post-synaptic density-95 (PSD95) (MAB 1596, Millipore). Horseradish peroxidise (HRP)-conjugated secondary antibodies (GE Healthcare) were detected using enhanced chemiluminescence (Thermo Fisher Scientific) and visualised using a ChemiDoc imager (Bio-Rad, CA, USA). Densitometric analysis was performed using Fiji (28).
Peptide Arrays
Tau peptide arrays were generated as described previously (33 
Data analysis and statistics
Statistical tests were performed using GraphPad Prism 7.0 (CA, USA) or RStudio.
Results
Tau and BIN1 interact
BIN1 and tau co-immunoprecipitate following over-expression of both proteins in cell lines, and the endogenous proteins interact in synaptoneurosomes isolated from mouse brain (12) . demonstrating that proline 216 in tau is critical for the tau-BIN1 interaction.
Phosphorylation of tau at serine and threonine residues affects its interactions with other SH3-domain containing proteins (38) . Tau in lysates from primary cortical neurons treated with 50 nM okadaic acid (OA), a protein phosphatase inhibitor (39, 40) , for 4 hours to increase tau phosphorylation ( Figure 3A ), showed only trace amounts of binding to BIN1-SH3-GST ( Figure 3B ). In similar experiments using lysates from neurons treated with 25 mM of the glycogen synthase-3 inhibitor lithium chloride (LiCl) (39, 41) ( Figure 3C ), or 20 μM of the casein kinase-1 inhibitor IC261 (39, 42) to dephosphorylate tau (Supplementary Figure 3A) , the amount of tau pulled down by BIN1-SH3 was similar to controls ( Figure   3D , Supplementary Figure 3B ). These data suggest that BIN1-tau interactions, mediated by BIN1-SH3   and   213 PxxPxxP 219 in tau, take place predominantly when tau is dephosphorylated.
BIN1 loss in cytoplasmic fractions of AD brain correlates with increased synaptic tau
In AD brain, highly phosphorylated tau is mislocalised to synaptic compartments (31) where tau is believed to exert toxicity (43, 44) , and there is a loss of the longest isoform of BIN1 (9, 10). We facilitates the mis-sorting of tau to the synapse.
BIN1 knockdown causes synaptic accumulation of phosphorylated tau in neurons
To investigate the effects of lowering BIN1 expression on tau mislocalisation, we knocked down BIN1
in rat primary cortical neurons using lentivirus. In control neurons, BIN1 and tau are found in both cytoplasmic and synaptic fractions ( When bound to tau, the non-receptor tyrosine kinase, Fyn, is trafficked to the post-synapses where it is believed to mediate -amyloid toxicity in AD (46) . We previously showed that the Fyn-SH3 domain also binds preferentially to proline 216 in tau (26, 37). We therefore examined Fyn localisation in synaptic fractions following BIN1 knockdown. We found no alterations in synaptic Fyn in neurons treated with BIN1 siRNA ( Figure 6H ), suggesting that Fyn does not compete with BIN1 for binding to tau.
Loss of BIN1 alters spine morphology and reduces tau release from neurons
Modulating BIN1 expression was recently shown to affect dendritic spine morphology and AMPA receptor-mediated synaptic transmission via changes in AMPA receptor surface expression and trafficking (22, 29). Since we and others have previously shown that neuronal depolarisation and stimulation of AMPA receptors mediates tau release (23, 27), we examined the effects of BIN1 knockdown on tau release. We first confirmed that BIN1 knockdown affects synaptic morphology in 23 DIV primary neurons exogenously expressing eGFP using iSIM. BIN1 knockdown did not cause any alterations in dendritic spine length, volume or density ( Figure 7A-D) , but resulted in significant increases in the diameter of spine heads and necks ( Figure 7E -F) and a reduced head:neck diameter ratio ( Figure 7G ). When spine morphologies were examined, BIN1 knockdown had no effect on the proportion of immature stubby or thin spines ( Figure 7H, I ), but significantly reduced the proportion of filopodia ( Figure 7K ) and increased the proportion of mature mushroom spines ( Figure 7J However, others have shown co-localisation between BIN1 and neurofibrillary tangles in AD brain (11) and have reported the existence of a tau-BIN1-clusterin complex in AD brain (52) . Our results suggest that changes in tau-BIN1 interactions may not be global but could occur primarily between BIN1 and largely dephosphorylated tau in neuronal cytoplasm. Increased tau phosphorylation in AD would disrupt tau binding to BIN1 and retention of tau in the cytoplasm, allowing phosphorylated tau to be mis-sorted to synapses.
Expression of the longest neuronal isoform of BIN1 is reported to be lost in AD (10) . We have extended this characterisation here to show a significant loss of cytoplasmic BIN1 from Braak stage III onwards in AD brain tissue. From Braak stage III this loss of BIN1 also showed a strong positive correlation with tau and mislocalisation of total and phosphorylated tau to the synaptic compartment, which may reflect an unbound pool of tau being phosphorylated and mis-sorted. In support of this idea, increased expression of BIN1 increases tau-BIN1 interactions and reduces tau-tubulin interactions (19), which would affect tau localisation. This is an important concept since alterations in the trafficking and normal positioning of tau are considered to be early pathogenic changes in AD (53-57).
To mirror the loss of BIN1 in AD, we knocked down BIN1 in rat primary neurons and this resulted in an accumulation of phosphorylated tau at synapses. In parallel, over-expression of BIN1 in mice expressing human tau led to a reduced number of somatodendritic tau inclusions (19). While tau has been observed at both the pre-and post-synapse in control post-mortem brain, phosphorylated tau is generally only found at the synapse in AD (32) where it is associated with loss of synaptic function, dysregulated calcium signalling, aberrant trafficking of glutamate receptors, and loss of mushroom spines (46, 58, 59) . It is tempting to speculate therefore, that loss of BIN1 could promote AD by allowing the accumulation of damaging forms of phosphorylated tau at the synapse.
We show here that BIN1 knockdown results in spines with a larger head and neck diameter and increases the ratio of more mature mushroom spines to immature filopodia. In agreement with this, BIN1 over-expression results in the opposite changes to spines, leading to structural alterations in the hippocampus and memory deficits (22, 60). Mushroom spines are considered to be more stable and in general as spine size increases the number of AMPA receptors on the spine increases, increasing synaptic strength (49, 61, 62) . This may appear to be in contrast with our assertion that BIN1 knockdown promotes synapse damage by directing phosphorylated tau into synapses. However, synapse enlargement is reported to occur in the early stages of neurodegeneration in AD (63) as a compensatory mechanism for the pre-synapse loss occurring early in the disease process (64), which could explain the increased spine diameter we report here. It is also possible that the effect of altering
BIN1 expression on dendritic spines is independent of its binding to tau. Schurmann et al. (29) report
that BIN1 modulates trafficking from recycling endosomes to the cell surface thereby altering the surface localisation of AMPA receptors in dendritic spines (29). Hence alterations in vesicle trafficking may be another mechanism by which BIN1 alters the structure of dendritic spines.
Finally, we demonstrate that loss of BIN1 expression results in reduced tau secretion from neurons, both in basal conditions and following neuronal depolarisation with KCl. We previously characterised the tau released from primary neurons as being largely intact, dephosphorylated (23), and likely to reflect trans-cellular signalling functions of extracellular tau (65, 66) , distinguishing it from the aggregated, cleaved and highly phosphorylated tau species implicated in trans-synaptic tau spread/propagation. The results in this study suggest that the function of intact dephosphorylated tau is disrupted when BIN1 is lost. However, several different mechanisms have been suggested to underlie tau secretion in health and disease (66, 67) . Tau fragments containing the proline-rich region are enriched among secreted tau fragments (67) while those lacking the proline-rich region are not secreted (65) . Our ELISA only allows measurement of tau containing the proline-rich region of tau, therefore we cannot rule out the possibility that the release of distinct tau fragments could also be affected by BIN1 knockdown. Nevertheless, we report a novel finding that lowering BIN1 levels, as occurs in AD, results in significant inhibition of tau release from wild-type rat neurons. This would doubtless affect trans-cellular signalling functions of tau, including that at muscarinic acetylcholine receptors (68) .
Our data demonstrate that BIN1 binds tau in a phosphorylation-dependent manner and this interaction is mediated by the BIN1-SH3 and tau proline-rich domains. We find that BIN1 is reduced in AD cytoplasm, and that this correlates with the loss of cytoplasmic tau and its accumulation in synaptic fractions. Modelling the loss of BIN1 in AD in primary neurons showed that when BIN1 is knocked down, mislocalisation of phosphorylated tau to synaptic fractions is increased, in parallel with reduced tau secretion. We hypothesise therefore, that disruptions to BIN1-tau interactions caused by BIN1 loss in AD enables tau-mediated synaptotoxicity and disrupts extracellular tau functions. Our data provide a potential mechanism by which polymorphisms near BIN1 may increase AD risk and/or progression. were transfected with a plasmid expressing eGFP and fixed at 23 DIV. Maximum intensity projections were generated from Z-stacks acquired using I-SIM super-resolution imaging. Dendritic spines were classified as either filopodia or stubby, thin or mushroom spines (right). Bar charts show quantification of spine B) length, C) volume, D) density, E) head diameter, F) neck diameter, G) ratio of spine head to neck diameter, and percentage of H) stubby, I) thin, J) mushroom spines and K) filopodia. Data are mean ± S.E.M. and were analysed using a randomised block 2-way ANOVA. n=3. *p<0.05, **p<0.01. western blotted with antibodies against BIN1 and total tau. B) Quantification shows no effect of BIN1 knockdown on tau amount. Shapiro-Wilk normality test demonstrated that the data were normally distributed and data were analysed using an unpaired T-test. C) Tau content in conditioned media from neurons was determined by ELISA. Tau content in medium was quantified relative to intracellular tau levels and shows reduced tau release upon BIN1 knockdown. Shapiro-Wilk normality test demonstrated that the data were normally distributed, so data were analysed using an unpaired Ttest. D) Cells transduced as above were depolarised with 50 nM KCl (+) for 30 minutes and the lysates were western blotted with antibodies against BIN1 and total tau. E) KCl treatment had no effect on intracellular tau amounts. Shapiro-Wilk normality test demonstrated that the data were normally distributed, so data were analysed using an unpaired T-test. F) Tau in conditioned media from KClstimulated cells was measured as described for basal conditions. Tau release from neurons in which BIN1 was knocked down remained reduced upon neuron depolarisation with KCl. Shapiro-Wilk normality test demonstrated that the data were not normally distributed, so data were analysed using a Mann-Whitney test. G) Lactate dehydrogenase amounts were measured in medium from unstimulated (-) or KCl-stimulated (+) primary cortical neurons transduced with scrambled control shRNA (Scr) lentivirus or BIN1 shRNA (BIN1) lentivirus and showed no effect of treatment on cell viability. Shapiro-Wilk normality test demonstrated that the data were not normally distributed, so data were analysed using a Kruskal-Wallis test with Dunn's multiple comparison test. All graphs show mean ± S.E.M, n=7 (intracellular tau) or 6 (tau release, and lactate dehydrogenase assay). *p<0.05. 
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